doi: 10.1016/j.cmet.2019.07.013 138 ZhangQDelessaCTAugustinRBakhtiMColldnGDruckerDJet al
Cold Spring Harbor Symposia on Quantitative Biology , 72, 579597
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
The most closely watched Ozempic-related cases remain part of a federal multidistrict litigation in Pennsylvania, where more than 3,000 plaintiffs allege GLP-1 drugs caused gastroparesis, or stomach paralysis
There is no objective measurement of GLP-1 levels or body composition changes
Stick to simple, easy-to-digest foods while adjusting to the medication